





































Està subjecte a una llicència de 
Reconeixement-NoComercial-SenseObraDerivada 3.0 de Creative Commons 
1 
 
The lipid type affects the in vitro digestibility and β-1 
carotene bioaccessibility of liquid or solid lipid 2 
nanoparticles 3 
Heloísa Helena de Abreu-Martinsb, María Artiga-Artigasa, Roberta Hilsdorf Piccolib, 4 
Olga Martín-Bellosoa, Laura Salvia-Trujilloa* 5 
 6 
aDepartment of Food Technology, University of Lleida – Agrotecnio Center, Av. Alcalde 7 
Rovira Roure 191, 25198. Lleida, Spain 8 
bDepartment of Food Science, Federal University of Lavras, Av. Dr Sylvio Menicucci 9 
1001, 37200000. Lavras, Brazil. 10 
*Author to whom correspondence should be addressed 11 
e-mail list: 12 
Heloísa Helena de Abreu-Martins heloisa_habreum@estudante.ufla.br 
María Artiga-Artigas maria.artiga@udl.cat 
Roberta Hilsdorf Piccoli rhpiccoli@dca.ufla.br 
Olga Martín-Belloso omartin@teca.udl.cat 
Laura Salvia-Trujillo lsalvia@tecal.udl.cat 
 13 
Submitted to <Food Chemistry> on <July, 2019> 14 
Running Title: 15 
<Digestibility of solid lipid nanoparticles> 16 
Keywords: 17 
Solid lipid nanoparticles; oil type; β-carotene; lipid digestibility; bioaccessibility 18 




Solid lipid nanoparticles (SLNs) are emulsion-based carriers of lipophilic bioactive 21 
compounds. However, their digestibility may be affected by the solid lipid phase 22 
composition. Hence, the aim of this work was to study the in vitro lipolysis kinetics as 23 
well as the relationship between the lipid digestion, micelle fraction composition and β-24 
carotene bioaccessibility of SLNs with different solid lipids, being blends of medium 25 
chain triglyceride (MCT) oil, glyceryl stearate (GS) or hydrogenated palm oil (HPO) as 26 
compared to liquid lipid nanoparticles (LLNs) with pure MCT. SLNs formulated with 27 
GS were fully digested, similarly to LLNs. However, HPO-containing SLNs presented 28 
slower lipolysis kinetics during the intestinal phase at increasing HPO concentration. 29 
Despite this, HPO-SLNs showed higher β-carotene bioaccessibility, which was related 30 
to the higher amount of monounstaturated free fatty acids in the micelle fraction. Thus, 31 
this work provides valuable insight for designing delivery systems of bioactive 32 
compounds with optimal functionality. 33 
  34 
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1 Introduction 35 
In recent years, there has been an increasing interest on the design of emulsion-based 36 
delivery systems of lipophilic bioactive ingredients in food systems. In this regard, the 37 
fabrication of nanoemulsions as carriers of active compounds has arose as a strategy to 38 
enhance the functionality of health-related ingredients (Salvia-Trujillo, Soliva-Fortuny, 39 
Rojas-Grau, McClements, & Martin-Belloso, 2017). Nanoemulsions are dispersions of 40 
two immiscible liquids, typically oil-in-water, with a droplet diameter smaller than 200 41 
nm (J. Rao & McClements, 2011). Nanoemulsions have shown a faster lipid 42 
digestibility kinetics under simulated gastrointestinal conditions in comparison with 43 
conventional emulsions with larger droplet sizes, which is attributed to their higher 44 
interfacial area able to interact with intestinal lipases (Salvia-Trujillo, Rojas-Graü, 45 
Soliva-Fortuny, & Martín-Belloso, 2013). This has been related with an enhancement of 46 
the functionality of lipophilic bioactive compounds, such as carotenoids. Carotenoids 47 
are hydrophobic micronutrients found in fruits and vegetables and their consumption 48 
has been associated with a reduced risk of cataract or cancer prevention (Rao & Rao, 49 
2007). However, they are poorly solubilized in the intestinal juices due to their 50 
lipophilic nature, thus showing a very low bioaccessibility. The use of nanoemulsions as 51 
carriers of carotenoids has shown to enhance their bioaccessibility, which has been 52 
highly related to the oil droplet digestibility (Salvia-Trujillo et al., 2017). The higher the 53 
concentration of free fatty acids released from the lipid digestion, the higher the 54 
concentration of lipid species in the micellar fraction, and subsequently, the higher 55 
carotenoid micellarization capacity (Salvia-Trujillo et al., 2017). However, this 56 
relationship may be affected by other emulsion characteristics and the lipid composition 57 
such as the fatty acid chain length (Salvia-Trujillo, Qian, Martín-Belloso, & 58 
McClements, 2013) or their unsaturation degree (Verkempinck, Salvia-Trujillo, Moens, 59 
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Carrillo, et al., 2018), showing different carotenoid micellarization capacity and 60 
therefore bioaccessibility. Additionally, also the type of carotenoid species present 61 
different intrinsic bioaccessibility, which is related to their hydrophobicity, being β-62 
carotene the one presenting the highest bioaccessibility (Palmero, Panozzo, Simatupang, 63 
Hendrickx, & Van Loey, 2014). 64 
Moreover, carotenoids are often highly sensitive to suffer degradation due to the 65 
exposure to oxidative agents in the environment (Boon, McClements, Weiss, & Decker, 66 
2010). Therefore, strategies are being sought in order to overcome their chemical 67 
instability. In this regard, solid lipid nanoparticles (SLNs), which are nanoemulsions yet 68 
consisting on a solid lipid core, have been reported to provide higher chemical stability 69 
of encapsulated lipophilic bioactive compounds in comparison with those formulated 70 
with liquid lipids (Muller, Mader, & Gohla, 2000; Nik, Langmaid, & Wright, 2012). 71 
This has been attributed to a reduced diffusion between the lipid core and the bulk 72 
aqueous phase (Salvia-Trujillo et al., 2019). However, depending on the crystallization 73 
state of the solid lipid core, an expulsion of the encapsulated bioactive compound may 74 
occur subsequently inducing a faster degradation (Weiss et al., 2008). In fact, certain 75 
solid fats may render tightly packed crystalline structures thus showing a faster 76 
degradation of carotenoids (Qian, Decker, Xiao, & McClements, 2013). In addition to 77 
this, differences have been observed in the lipid digestibility of emulsified solid lipids in 78 
comparison with liquid oils, by presenting a delayed lipolysis (Guo, Bellissimo, & 79 
Rousseau, 2017; Nik, Langmaid, & Wright, 2012; Salvia-Trujillo et al., 2019b). This 80 
behavior has being attributed to a hindered lipase adsorption onto lipid-water interfaces 81 
(Bonnaire et al., 2008), which might create opportunities towards a controlled lipid 82 
digestibility of such delivery systems. Nonetheless, most of recent research works 83 
dealing with the study of edible SLNs as delivery systems of bioactive compounds have 84 
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been conducted with purified solid lipids such as tripalmitin or tristearin among other 85 
triglycerides that are solid at room temperature (Mehnert & Mäder, 2001; Qian et al., 86 
2013). However, the extrapolation of these studies to SLNs fabricated with 87 
commercially available solid fats is limited due to that solid fats are more complex in 88 
triglyceride composition and therefore they may present a different behavior during 89 
digestive conditions. Therefore, there is a need for a deeper understanding on the 90 
influence of the solid fat type and composition on the lipid digestibility kinetics and its 91 
relationship with the bioaccessibility of the encapsulated bioactive compounds.  92 
Hence, the aim of this work was to study the fate during in vitro digestive conditions of 93 
liquid lipid nanoparticles (LLNs), also known as nanoemulsions, with medium chain 94 
tryglyceride oil (MCT) and SLNs formulated with lipid phases consisting on blends of 95 
MCT and two different solid lipid types, being glyceryl stearate (GS) or partially 96 
hydrogenated palm oil (HPO) at different concentrations as carriers of β-carotene. GS is 97 
a monoglyceride composed mainly of stearic acid (C18:0), which is typically used as 98 
surfactant in the food industry, while partially HPO is a triglyceride mainly consisting 99 
on palmitic (C16:0) and stearic acid (C18:0). For this purpose, the influence of the 100 
concentration of each solid fat on the in vitro lipid digestibility kinetics and the 101 
relationship with the β-carotene bioaccessibility was evaluated. Additionally, the 102 
micellar fraction composition was analyzed in order to identify the lipid species 103 




2 Material and Methods 106 
2.1 Materials 107 
MCT oil (Mygliol® 812N) and GS (Imwitor® 491) with a purity of 99.9% and 96.7% 108 
(0.8% free glycerol and 95.9% monoglycerides), respectively, according to their 109 
certificate of analysis were purchased from IOI Oleochemical GmbH (Hamburg, 110 
Germany) and organic HPO containing ≤0.1 free fatty acids was acquired from Mystic 111 
Moments (Hants, UK). Tween 80, synthetic β-carotene (purity ≥ 93 %) and the rest of 112 
chemicals used in this study were purchased from Sigma-Aldrich, Inc. (St. Louis, MO, 113 
USA). Ethanol and hexane were from Fischer Scientific (Madrid, Spain). LLNs and 114 
SLNs were formulated with ultrapure water obtained from a Milli-Q filtration system 115 
(18.2 mΩ, Merck Millipore, Madrid, Spain). 116 
2.2 Formation of liquid or solid lipid nanoparticles 117 
LLNs with pure MCT or SLNs  with different lipid phases consisting on blends of MCT 118 
and GS or HPO were formulated. GS or HPO were firstly melted by increasing the 119 
temperature at 60 ºC and subsequently were mixed with magnetic stirring at 500 rpm for 120 
10 min with MCT at the same temperature. Specifically, the lipid phases containing GS 121 
were formulated with a 0.5, 1 or 5 % (w/w) of GS and the rest MCT, while those with 122 
HPO were blends of MCT:HPO at different ratios, being 50:50, 25:75 and 0:100. The 123 
selection of the concentration of GS and HPO, respectively, for the formulation of  124 
SLNs was done according to the minimum concentration that led to a solid lipid blend 125 
after being cooled down at 4 ºC for 1 hour, and the maximum concentration was set to 126 
the one that allowed the subsequent emulsification by microfluidization without risk of 127 
clogging. The concentration range tested for the two solid lipids was set according to 128 
the differences in their solidification behavior at room temperature and to avoid the 129 
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clogging risk of the high-pressure homogenization device during emulsification. The 130 
thermal properties of the lipid blends were characterized by differential scanning 131 
calorimetry (Mettler-Toledo 822e, Barcelona, Spain) from -20 to 80 ºC at 1 K/min 132 
(supplementary material, Tables A and B). Afterwards LLNs or SLNs were prepared 133 
by cold or hot high-pressure homogenization technique respectively, maintaining 134 
emulsions slightly above 60 ºC in order to avoid fat crystallization during the 135 
emulsification step in the case of the SLNs. Firstly, coarse emulsions were prepared by 136 
mixing the lipid phase at a 5 % (w/w), Tween 80 at a 2,5 % (w/w) as surfactant and the 137 
92.5% of aqueous phase with a high-speed blender (Ultra-Turrax T25 homogenizer, 138 
IKA® Works, Inc. Wilmington, NC, USA) working at 7600 rpm for 3 min. The coarse 139 
emulsions were subsequently passed through a microfluidizer (MP-110 Microfluidics, 140 
MA, USA) at 70 MPa for 3 cycles. Afterwards, the temperature of LLNs or SLNs was 141 
reduced down to 4 ºC for 2 h in order to allow fat recrystallization. 142 
2.3 In vitro digestion 143 
The in vitro digestibility of LLNs and SLNs was conducted according to the 144 
INFOGEST international consensus (Minekus et al., 2014), consisting on a gastric and 145 
intestinal phase. Simulated gastric fluid solution (SGF) was consisted on a mixture of 146 
electrolytes [0.5 M KCl, 0.5 M KH2PO4, 1 M NaCl, 2 M NaCl, 0.15 M MgCl2(H2O), 147 
0.5 M (NH4)2CO3] dissolved in 20 mL of milli-Q water. Then, 18.2 mL of SGF was 148 
acidified adding 1.8 mL of 0.02 M HCl, and used to dissolve the pepsin (8.8 mg/mL). 149 
Gastric digestion was performed by mixing 20 mL of LLNs or SLNPs with 20 mL of 150 
SGF solution. The mixture was incubated under subdued light conditions for 2 h at 37 151 
°C and continuous agitation using an orbital shaker working at 100 rpm. Afterwards, a 152 
30 mL-aliquot of the chyme was placed in a water bath at 37 °C. Subsequently, in order 153 
to simulate the small intestinal phase, 3.5 mL of bile salts (54 mg/mL) and 1.5 mL of 154 
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intestinal salts (10 mM of CaCl2 and 160 mM of NaCl) were added to the sample, and 155 
the pH was adjusted to 7.0. Then, 2,5 mL of pancreatin (215 mg/mL) solution was 156 
added to the sample to initiate the lipid hydrolysis. The lipolysis reaction was monitored 157 
with a titration unit (pH-stat, Metrohm USA Inc., Riverview, FL, USA), which 158 
maintained the pH of the digest at 7. After this, digest samples were transferred into 159 
glass tubes and heat-shocked at 85 °C for 5 min in order to stop the lipolysis reaction 160 
and placed in an iced-water bath afterwards. The free fatty acid (FFA) release in 161 
percentage was calculated according to equation 1: 162 
𝐹𝐹𝐴 (%) =  
𝑉𝑁𝑎𝑂𝐻𝑥 𝐶𝑁𝑎𝑂𝐻 𝑥 𝑀𝑜𝑖𝑙
2 𝑥 𝑚𝑜𝑖𝑙
 𝑥 100     Equation (1) 163 
where VNaOH is the NaOH volume needed to neutralize FFA released during the lipolysis 164 
reaction, CNaOH is the Molar concentration of NaOH (0.25 M), Moil is the molecular 165 
weight of the lipid phase (g/mol) and moil is the total oil weight in the 30-mL aliquot 166 
placed in the titration unit. The molecular weight of MCT oil, GS and HPO was 506, 167 
1704 and 828 g/mol, respectively, and that of the blends was calculated taking into 168 
account the amount of each lipid component in the lipid phase.  169 
2.4 Particle size and particle size distribution 170 
The particle size and particle size distribution was measured by either dynamic or static 171 
light scattering technique using a Zetasizer Nano ZS or a Mastersizer 3000 (Malvern 172 
Instruments Ltd, Worcestershire, UK), respectively. For dynamic light scattering 173 
measurements sample was diluted 1:100 in MilliQ water and the particle size was 174 
reported as z-average (µm). For static light scattering measurements, sample was 175 
dispersed in a liquid dispersion unit and the particle size was reported as volume-176 
weighted average (d4,3). 177 
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2.5 ζ-potential 178 
The ζ-potential (mV) was measured by phase-analysis light scattering (PALS) with a 179 
Zetasizer Nano ZS laser diffractometer (Malvern Instruments Ltd, Worcestershire, UK). 180 
Samples were prior diluted in ultrapure water using a dilution factor of 1:150 sample-to-181 
solvent. 182 
2.6 Microscopy 183 
Phase contrast microscopy images of undiluted initial LLNs and SLNs and after being 184 
submitted to gastric and intestinal conditions were taken with an optical microscope 185 
(BX41, Olympus, Göttingen, Germany) equipped with UIS2 optical system. All images 186 
were processed using the instrument software (Olympus cellSense, Barcelona, Spain). 187 
2.7 β-carotene bioaccessibility 188 
The β-carotene bioaccessibility from LLNs and SLNs with different lipid phase 189 
composition was determined after the samples had been subjected to the prior described 190 
in vitro digestion procedure. An aliquot of the digest was ultracentrifuged (AVANTI J-191 
25, Beckman Instruments Inc., Fullerton, CA, USA) at 15000 rpm for 40 min at a 192 
temperature of 8 °C. The supernatant, being the aqueous fraction containing the mixed 193 
micelles, was collected and was considered to be the micelle fraction in which the β-194 
carotene is solubilized. The β-carotene quantification was conducted by the method 195 
reported by Liu et al. (2018), where a 0.5 mL-aliquot of the initial LLNs or SLNs and 196 
the micellar fraction was mixed with 2 mL of ethanol and 3 mL of hexane and vortexed 197 
for 10 s. Afterwards, the upper hexane phase containing the β-carotene was transferred 198 
to a test tube and the extraction was repeated two times until the ethanol lower layer was 199 
clear. The hexane fraction was analyzed spectrophotometrically (CECIL CE 2021; Cecil 200 
Instruments Ltd, Cambridge, UK) at 450 nm. The concentration of β-carotene extracted 201 
from a sample was determined from a calibration curve of absorbance versus β-carotene 202 
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concentration in hexane. The bioaccessibility was then calculated using the following 203 
equation: 204 
𝐵𝐴 =  
𝐶𝑚𝑖𝑐𝑒𝑙𝑙𝑒
𝐶𝑖𝑛𝑖𝑡𝑖𝑎𝑙
× 100       Equation (2) 205 
where Cmicelle and Cinitial are the β-carotene concentration in the micellar fraction and the 206 
initial LLNs or SLNs, respectively. 207 
2.8 Micellar fraction analysis 208 
The micelle fraction of the digested LLNs and SLNs formulated with different lipid 209 
phases was characterized in terms of their concentration of lipid digestion products. A 210 
1-mL aliquot of the micelle fraction was mixed with 2 mL of ethanol, 3 mL of 211 
diethylether:heptane (1:1) and 0.2 mL of sulphuric acid (2.5 M), vortexed for 2 min and 212 
further stirred at 200 rpm during 30 min. Afterwards, the top layer was collected in a 5 213 
mL volumetric flask containing 100 mg of Na2SO4 (anhydrous). The bottom layer was 214 
mixed with 1 mL of diethylether:heptane (1:1) and the process was repeated and stirred 215 
for 15 min. The organic layer was added to the previous one and the volume was 216 
brought up to 5 mL. The lipid extract was kept at −40 °C until analysis. The analysis 217 
and relative quantification of the lipid digestion products was carried out with a 6890-218 
5973 Gas Chromatograph-Mass Spectrometer (GC-MS) (Agilent Technologies, USA) 219 
based on a method previously proposed with some modifications (Verrijssen et al., 220 
2016). In the GC with a capillary column ZEBRON ZB-1HT (15 m x 0.32 mm x 0.25 221 
µm) (Inferno™, Phenomenex, Madrid, Spain), 0.5 μL sample was injected on-column. 222 
The oven temperature started at 80 °C and increased to 400 °C through a first ramp of 6 223 
°C/min up to 280ºC followed by a second one of 30ºC/min until 380ºC (1 min). An MS-224 
system (Agilent Technologies, 5973 Inert Mass Selective Detector, Diegem, Belgium, 225 
U.S.A) was used to detect the compounds. Nist 11 Mass spectral library was used as 226 
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standard reference database for the identification of FFAs and MAGs (FarHawk 227 
Marketing Services, U.S.A). The quantification of FFAs and MAGs was carried out by 228 
comparison with standard curves of decanoic acid (C10:0), dodecanoic acid (C12:0), 229 
myristic acid (C14:0), palmitic acid (C16:0), stearic acid (C18:0) and oleic acid (C18:1) 230 
for FFAs and 1-octanoyl-rac-glycerol (MAG-C8:0), 1-decanoyl-rac-glycerol (MAG-231 
C10:0), 2-palmitoylglicerol (MAG-C16:0), 1-oleoyl-rac-glycerol (MAG-C18:1) for 232 
MAGs.  233 
2.9 Lipolysis kinetics  234 
The kinetics of the lipolysis reaction at early time moments (35 min) of the in vitro 235 
small intestinal phase of LLNs or SLNs formulated with GS or HPO at different 236 
concentrations was evaluated by fitting a logistic model consisting of 3 estimated 237 




       Equation (3) 239 
 240 
where FFA(t) is the free fatty acid release (%) during small intestinal phase time (t), a is 241 
the inflexion point of the curve (min); b is the asymptotic value of the curve (%) when 242 
small intestinal phase time (t) is ∞; and k is the reaction rate constant (min-1). 243 
Estimated parameters were determined by non-linear regression using the JMP Pro 14 244 
statistical software (SAS Institute Inc.). The fit of the model was assessed by calculating 245 
R2 and visually analyzing the residue plots. Significant differences between the 246 
estimated parameters of different samples were determined by calculating the 247 
confidence intervals (95%). 248 
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2.10 Statistical analysis 249 
All experiments were performed in duplicate, using at least two measurements of each 250 
determination. An analysis of variance was carried out and the Student’s t test was run 251 
to determine significant differences at a 5% significance level (p < 0.05) with statistical 252 
software JMP Pro 14 (SAS Institute Inc.). 253 
3 Results and discussion 254 
The influence of the lipid phase state of LLNs or SLNs formulated with GS or HPO 255 
during in vitro digestive conditions was studied in terms of (i) their colloidal stability 256 
through their particle size, particle size distribution, microstructure and ζ-potential; (ii) 257 
their lipoplysis kinetics during small intestinal phase by determining the FFA release; 258 
(iii) the β-carotene bioaccessibility after the in vitro digestive conditions and (iv) the 259 
composition of the micellar fraction in terms of lipid species in order to elucidate the 260 
relationship between the lipolysis kinetics, the β-carotene bioaccessibility and the 261 
micellar fraction composition. 262 
3.1 Colloidal stability during in vitro digestion 263 
The stability of initial LLNs or SLNs containing GS or HPO at different ratios after 264 
being submitted to simulated gastric and small intestinal phases was studied. 265 
Particle size, particle size distribution and microstructure 266 
The initial particle size of LLNs containing pure MCT was 0.110 ± 0.013 µm while 267 
SLNs formulated with MCT and GS presented slightly yet significantly smaller particle 268 
sizes, with values of 0.987 ± 0.001 µm in SLNs formulated with 1 % GS in the lipid 269 
phase (Figure 1A). In fact, GS is a monoglyceride with interfacial activity, thus 270 
contributing to some extent to the particle size reduction during emulsification. Despite 271 
this, no significant differences were observed after increasing the concentration of GS in 272 
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the lipid phase of SLN, suggesting that a concentration of 0.5% is enough to evidence 273 
its emulsifying capacity, without presenting a significant reduction in the particle size of 274 
SLN when used at higher concentrations. However, SLNs formulated with HPO 275 
presented a significantly higher initial droplet size (0.136 ± 0.001 µm) in comparison 276 
with pure MCT LLNs (Figure 1B), which may be attributed to the higher viscosity of 277 
solid fats, such as HPO, in comparison with oils with medium chain triglycerides. In 278 
this regard, microscopy images evidenced a larger droplet size in those SLNs 279 
formulated with a 25:75 MCT:HPO ratio and pure HPO (supplementary material, 280 
Figure D). Initial LLNs or SLNs formulated with either GS or HPO presented narrow 281 
particle size distribution (Figure 2A, D) and microscopy images showed homogeneous 282 
dispersion of lipid droplets (supplementary material, Figure C and D). 283 
On the one hand, after simulated gastric conditions, the particle size of LLNs with MCT 284 
or SLNs with GS or HPO remained stable (Figure 1A, B). In fact, it has been 285 
previously reported that Tween 80 is a non-ionic surfactant, which is not sensitive to pH 286 
changes in the gastric phase (pH 3), thus showing higher stability of emulsion-based 287 
systems in the stomach in comparison with other emulsifiers (Verkempinck, Salvia-288 
Trujillo, Moens, Charleer, et al., 2018). This was confirmed by the results of particle 289 
size distribution (Figure 2B, E) and microscopy images (supplementary material, 290 
Figure C and D), which showed the same results than initial MCT LLNs and SLNs. 291 
Regarding the end of the small intestinal phase, a large increase in the particle size of 292 
MCT LLNs and SLNs was observed. In the case of MCT LLNs, the surface-weight 293 
(d32) average particle diameter was 91 ± 5 µm, while it was smaller in those SLNs 294 
containing GS. Actually, significantly smaller particle size of the digest was observed as 295 
increasing the GS concentration in the SLN formulation. The d32 values for SLNs 296 
containing 0.5, 1 or 5 % (w/w) of GS in the lipid phase after being submitted to small 297 
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intestine conditions were 17 ± 3, 11 ± 2 and 7 ± 1 µm, respectively. Despite that the 298 
particle size distribution presented multimodal curves after intestinal conditions (Figure 299 
2C), it was observed that LLNs with MCT presented a particle size distribution with a 300 
main intensity peak of large particles around 100 µm, while the particle size distribution 301 
of SLN presented intensity peaks of smaller particles. This suggests that, stearic acid 302 
released after lipolysis of GS may contribute to some extent to the emulsification of 303 
lipid species after the lipid hydrolysis. With regards SLN formulated with HPO, their 304 
particle size increase after small intestine conditions (Figure 1F) was less pronounced 305 
in comparison with those formulate with GS. The d32 values of SLNs at the end of the 306 
intestinal phase ranged between 0.69 ± 0.04 and 1.43 ± 0.36 µm, with intensity peaks in 307 
the particle size distribution below 10 µm, which might be attributed to the presence of 308 
undigested lipid particles from the SLNs containing HPO Additionally, microscopy 309 
images (supplementary material, Figure C) showed the presence of fibrous-like 310 
particles in those samples formulated with GS, which might be attributed to the 311 
crystallization FFA released, such as stearic acid, due to the decrease of temperature 312 
during the microscopy examination. Oppositely, HPO-containing SLNs presented 313 
smaller undigested solid lipid particles (supplementary material, Figure D). 314 
ζ-potential 315 
The particle electrical charge (ζ-potential) of LLNs with MCT and SLNs formulated 316 
with GS or HPO at different concentrations before and after being subjected to 317 
simulated gastric and small intestinal phases is presented in Figure 3. In this context, 318 
the ζ-potential of lipid particles might contribute in explaining differences in the 319 
stability during digestion and lipolysis degree. Initially, LLNs and SLNs showed 320 
negatively charged interfaces, with ζ-potential values ranging between -25.9 and -28.8 321 
mV, without significant differences between them (Figure 3). In fact, the surfactant 322 
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used in this study (Tween 80) is a non-ionic emulsifier that has shown to present 323 
negative charge in emulsions and nanoemulsions at certain pH conditions (Salvia-324 
Trujillo, Qian, Martín-Belloso, & McClements, 2013). After gastric conditions, both 325 
LLNs and SNLs formulated with GS or HPO exhibited a drastic decrease in the particle 326 
electrical charge, being less negatively charged, with values between -6.7 and -10.4 mV 327 
(Figure 3). This decrease in the ζ-potential after gastric conditions might be due to the 328 
lower pH (3) at the stomach phase, thus reducing the ionization degree of negatively 329 
charged groups. Nonetheless, after small intestinal conditions, the ζ-potential of the 330 
digested MCT LLNs and SLNs with GS and HPO at different concentrations decreased, 331 
observing differences between SLNs formulated with GS and HPO. On the one hand, 332 
LLNs and SLNs formulated with GS presented similar ζ-potential values after small 333 
intestinal conditions, with values ranging between -29.9 and -34.1 mV, without 334 
significant differences among SLNs with different GS concentrations (Figure 3). On 335 
the other hand, the ζ-potential of SLNs formulated with HPO was significantly more 336 
negative after small intestinal phase at increasing HPO concentration in the lipid phase 337 
(Figure 3). In this sense, the ζ-potential of MCT LLNs was -30.3 mV after small 338 
intestinal conditions, and it was -48.4, -51.6 and -52.5 mV in SLNs containing HPO at 339 
increasing concentrations being 50, 75 and 100 % HPO, respectively (Figure 3). It has 340 
been reported that the negative charge of digested emulsion-based systems after small 341 
intestinal phase can be attributed to the presence of anionic free fatty acids and other 342 
lipid digestion products from lipid hydrolysis (Singh, Ye, & Horne, 2009). However, 343 
our results show that SLNs formulated with increasing HPO concentration in the lipid 344 
phase, which had a more negative ζ-potential, where those that showed a lower lipid 345 
digestibility and therefore a lower FFA release (section 3.2). Therefore, this suggests 346 
that not only the concentration of lipid species released at the end of the intestinal phase 347 
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determines the charge of the digested samples, but also the FFA chain length plays a 348 
key role on the charge of the digest. In this regard, it has been reported that the negative 349 
charge of digested samples decreases at increasing the chain length of the released FFA 350 
(Salvia-Trujillo et al., 2013). In fact, HPO mainly contains long chain fatty acids while 351 
MCT contains medium chain fatty acids, thus explaining the differences in ζ-potential 352 
after small intestinal conditions. 353 
3.2 Lipolysis kinetics during in vitro small intestinal phase 354 
The lipolysis reaction was monitored during the in vitro small intestinal phase through 355 
the FFA release (%) in order to determine differences between the behavior during lipid 356 
digestion of LLNs and SLNs formulated with different concentration of GS or HPO 357 
hence different solidification degrees (Figure 4). 358 
For all the studied LLNs and SLNs, the lipid digestion reaction followed a sigmoidal-359 
shape curve, with a start of the lipolysis reaction immediately at the beginning of the 360 
intestinal phase and subsequently followed by an exponential increase in the FFA 361 
release at digestion time moments below 20 min. After this point, a steady-state zone 362 
was reached, with a residual increase of the FFA until the end of the intestinal phase. 363 
Nonetheless, both the lipid digestion kinetics at the beginning of the intestinal phase and 364 
end-point values of FFA release were highly dependent on the lipid phase formulation, 365 
with significant differences between LLNs and SLNs. Additionally, differences could 366 
be established between the lipolysis kinetics of GS and HPO-containing SLNs.  367 
On the one hand, MCT LLNs and the GS-containing SLNs presented similar lipid 368 
digestion kinetics regardless the concentration of GS in the lipid blend (Figure 4A). In 369 
fact, they presented similar rate constants (k-values) with values ranging between 0.328 370 
and 0.351 (Table A, supplementary material). Therefore, this evidences that the 371 
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solidification of the lipid phase by adding GS to MCT does not affect their lipid 372 
digestibility kinetics. Nevertheless, at increasing GS concentration in the lipid phase, 373 
SLNs reached slightly higher FFA values at the curve asymptote (Figure 4A, Table A, 374 
supplementary material), which lead to significantly higher values of FFA release at 375 
the end of the intestinal phase (Figure 4C). For instance, MCT LLNs led to FFA release 376 
asymptotic values of 86.34 ± 0.96 %, while SLNs with 5 % (w/w) GS led to 98.37 ± 377 
1.09 % FFA release. This might be due to the direct hydrolysis of stearic acid in the GS 378 
molecule, thus contributing to the overall lipid digestibility (Levy, Goldstein, Freier, & 379 
Shafrir, 1981). In fact, from triacylglycerols (TAG) hydrolysis, FFA and 380 
monoacylglycerols (MAG) are released. Pancreatic lipases present 1,3-n 381 
stereospecificity during TAG hydrolysis thus 2-n MAG normally remain undigested. 382 
Therefore, this suggests that GS may contain stearic acid in the 1- or 3-n positions, since 383 
it is hydrolyzed during small intestinal digestion of SLNs formulated with GS, 384 
accounting for the overall FFA release values. 385 
On the contrary, the lipid digestibility kinetics and extent during the small intestinal 386 
phase of SLNs containing HPO was highly dependent on the concentration of HPO in 387 
the formulation of the lipid phase (Figure 4B, D). At early time moments of the small 388 
intestinal phase, there was a significant delay in the initiation of the lipolysis reaction at 389 
increasing concentrations of HPO, observing the slowest lipid digestion kinetics in 390 
SLNs formulated with 100% HPO as lipid phase (Figure 4B). This was evidenced by 391 
the estimated kinetic parameters of the sigmoidal equation (Eq. 3) used to model the 392 
FFA release data (Table B, Supplementary material). In fact, there was a significant 393 
increase in the k-values of those SLNs with MCT:HPO 50:50 or 25:75, being 0.476 and 394 
0.460, in comparison with MCT LLNs, with a k- value of 0.351. Conversely, the 395 
asymptotic estimated parameter of SLNs formulated with 100% HPO evidenced that 396 
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there was a significantly lower FFA release in comparison SLNs with lower HPO 397 
content, reaching to values of 56.92 ± 2.55 % after 35 min of small intestinal phase, 398 
while it was 86.34 ± 0.96 % in MCT LLNs. This trend was maintained until the end of 399 
the small intestinal phase, where a lower lipid hydrolysis was observed in SLNs 400 
formulated at increasing concentration of HPO after 2 hours of intestinal conditions. In 401 
this regard, at the end of the intestinal phase, SLNs with 100% HPO presented 62 % 402 
FFA release, while MCT LLNs were fully digested, with a 100 % FFA release (Figure 403 
4C).  404 
The results of the current work evidence that lipid digestion kinetics is highly related to 405 
the specific crystalline state of the particular solid fats used as dispersed phase of SLNs. 406 
In fact, this might be attributed to the higher melting temperatures of HPO-containing 407 
SLNs in comparison with GS-containing SLNs, as observed in the DSC profiles of their 408 
respective lipid phases (Supplementary material, Figures A and B). Besides this, also 409 
the chain length of the fatty acids composing the triacylglycerol profile of the fats used 410 
in this work might contribute in explaining the differences observed. In fact, it is known 411 
that medium chain oils, such as MCT, present a faster and higher FFA release than long 412 
chain fatty acids in fats such as those present in HPO (Salvia-Trujillo et al., 2013), 413 
being attributed to that medium chain fatty acids are able to migrate more rapidly to the 414 
aqueous phase while long chain fatty acids tend to accumulate at the oil-water interface 415 
thus presenting a slower digestibility. Similarly to our findings, Guo et al. (2018) 416 
observed no significant differences between the lipid digestibility kinetics of emulsions 417 
stabilized with glyceryl monooleate or glyceryl monostearate, as liquid or solid 418 
emulsifiers, respectively. Moreover, other authors have reported that GS digestibility 419 
may not be concentration dependent, showing fast lipid digestibility regardless of the 420 
GS concentration in the lipid phase (Wang et al., 2017). Therefore, this suggests that 421 
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factors other than the lipid state may determine lipid digestibility of SLNs. In this 422 
context, Witzleb et al. (2012) observed that despite that both glyceryl monostearate and 423 
glyceryl tripalmitate are solid lipids, the former presented a much higher digestibility in 424 
comparison with glyceryl tripalmitate. Similarly, other authors have reported a much 425 
lower lipid digestibility in solid triacylglycerols such as tripalmitin, hydrogenated soy 426 
oil or cocoa butter in comparison with liquid dispersed phases (Bonnaire et al., 2008; 427 
Guo et al., 2017; Hart, Lin, Thilakarathna, & Wright, 2018). These differences in the 428 
lipid digestion behavior between solid monoacylglycerides and tryglycerides may be 429 
attributed to (i) the higher solubility of glyceryl monostearate in comparison with 430 
triacylglycerols thus being more accessible by pancreatic lipases and to (ii) the 431 
preference of intestinal lipase for MAG molecules such as glyceryl monostearate in 432 
comparison with TAGs.  433 
 434 
3.3 β-carotene bioaccessibility after in vitro digestion 435 
The concentration of β-carotene in the micelle fraction was determined and related to 436 
the initial concentration in LLNs and SLNs, thus accounting for the percentage of β-437 
carotene that was incorporated into mixed micelles, being referred to as β-carotene 438 
bioaccessibility (Figure 5A, B). Additionally, the final amount of FFA released (%) at 439 
the end of the intestinal phase (120 min) was plotted in order to relate the β-carotene 440 
bioaccessibility with the lipid hydrolysis degree. 441 
On the one hand, the β-carotene bioaccessibility of LLNs or GS-SLNs and their 442 
respective lipid digestion extent at the end of the intestinal phase were not positively 443 
correlated. In this regard, despite that the FFA release increased at increasing the GS 444 
concentration in the lipid blend, which was attributed to the digestion of GS 445 
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monoglyceride, the β-carotene bioaccessibility did not increase. In this sense, the β-446 
carotene bioaccessibility was 28.1  2.1 % in MCT LLNs and was practically similar or 447 
even slightly lower in the case of SLNs containing GS in the lipid phase (Figure 5A), 448 
being 25.8  0.4, 22.6  0.9 and 26.7  0.4 % for SLNs with 0.5, 1 and 5% (w/w) GS, 449 
respectively. Nevertheless, the opposite behavior was observed in SLNs containing 450 
HPO in the lipid phase (Figure 5B). The lipolysis extent of the HPO-containing SLNs 451 
decreased at increasing the HPO concentration the lipid blend, yet the β-carotene 452 
bioaccessibility significantly increased. In this regard, the lipid digestion was decreased 453 
at the end of the intestinal phase from 106  3 % in the MCT LLNs to 62  2 % in the 454 
SLN formulated with pure HPO as lipid phase, while the β-carotene bioaccessibility 455 
increased from 28.1  2.1 % up to 35.7  1.4 %, respectively. Our results are in 456 
controversy with the generally accepted statement that a higher the concentration of 457 
lipid species in the digest might be positively correlated with an increase in the mixed 458 
micelles micellarization capacity of lipophilic bioactive compounds such as carotenoids 459 
(Singh et al., 2009). In this context, our results evidence that not only the degree of 460 
lipolysis during digestion, but also the type of micellarized lipid species might 461 
determine their β-carotene solubilization capacity as discussed in the following section.  462 
 463 
3.4 Micellar fraction composition 464 
The micelle fraction composition was characterized in terms of the concentration of 465 
FFA and MAGs after small intestinal conditions in order to identify those lipid species 466 
that are micellarized after being hydrolyzed (Figure 6) and that might be responsible for 467 
the β-carotene bioaccessibility.  468 
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On the one hand, the micelle fraction of LLNs and SLNs containing a blend of MCT 469 
and GS after being digested was composed mainly of caprylic (C8:0) and capric (C10:0) 470 
acids (Figure 6A), which are the main medium chain fatty acids present in MCT oil. In 471 
this regard, the concentration of caprylic and capric acids in the micelle fraction of the 472 
MCT LLNs was 154  2 and 122  2 mg/mL of micellar fraction, respectively. At 473 
increasing the concentration of GS in the lipid blend of SLNs, the concentration of long 474 
chain FFA in the micelle fraction increased, detecting the presence of stearic (C18:0) 475 
and oleic (C18:1) FFA, in expense of the concentration of medium chain fatty acids 476 
(C8:0 and C10:0), which decreased. The concentration of stearic FFA in the micelle 477 
fraction of SLNs had increasing values of 3.4  0.3, 6.5  1.2 and 8.6  0.7 mg/mL at 478 
increasing the concentration of GS in the lipid blend. Additionally, the concentration of 479 
oleic acid ranged between 4.4  0.9 and 5.8  1.6 mg/mL of micelle fraction, regardless 480 
the concentration of GS in the lipid blend. A residual amount of palmitic FFA (C16:0) 481 
was detected in MCT LLNs and SLNs containing GS, with concentrations ranging 482 
between 1.02  0.5 and 1.55  0.8 mg/mL of micelle fraction. Furthermore, the presence 483 
of monocaprylin (MAG-C8:0) and monocaprilate (MAG-C10:0) was detected in SLNs 484 
containing 0.5 or 1 % (w/w) GS (Figure 6B). This results are in agreement with the 485 
lipid digestion kinetics results of the present work (Figure 4A, C), where a higher 486 
amount of FFA release was found, being attributed to the hydrolysis of the stearic acid 487 
of GS molecule. In fact, the absence of GS as monoglyceride form in the micelle 488 
fraction and the presence of stearic FFA instead support these results. However, the 489 
higher concentration of long chain fatty acids in the micelle fraction of SLNs with GS 490 
was not positively correlated with the β-carotene bioaccessibility results (Figure 5A), 491 
presenting a similar or even lower β-carotene bioaccessibility at the end of the intestinal 492 
phase. These findings are in controversy with previous reports evidencing that long 493 
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chain FFA may lead to a higher solubilization capacity of lipid species such as 494 
carotenoids (Salvia-Trujillo et al., 2013), being postulated to that long chain fatty acids 495 
may form larger mixed micelles, thus being able to better accommodate carotenoids in 496 
their inner core. Nevertheless, molecular characteristics other than the chain length 497 
might be involved in determining the mixed micelles solubilization capacity of 498 
lipophilic bioactive compounds. 499 
On the other hand, the micelle fraction of SLNs formulated with a blend of MCT:HPO 500 
as lipid phase presented a higher concentration of long chain FFA (Figure 5C), being 501 
higher than that observed for SLNs containing GS (Figure 5A). In fact, the 502 
concentration of medium chain FFA such as caprylic and capric acids decreased, from 503 
values above 120 mg/mL in the micelle fraction of the MCT LLNs down to values 504 
below 60 mg/mL in the SLNs with MCT:HPO 50:50. At the same time, the 505 
concentration of long chain FFA, such as palmitic, stearic and oleic increased. For 506 
instance, the concentration of oleic FFA increased up to 16.5  1.4, 31.7  2.1 and 55.2 507 
 3.3 mg/mL in the micelle fraction of SLNs containing MCT:HPO 50:50, 25:75 and 508 
0:100, respectively. Additionally, significant amounts of MAGs with long chain fatty 509 
acid esters were found in the micelle fraction of HPO-containing SLNs (Figure 6D). In 510 
this regard, monopalmitin and monolein were found in concentrations around 2.8  0.1 511 
and 2.0  0.1 mg/mL respectively, regardless the HPO concentration in the lipid blend. 512 
These results support that monounsaturated long chain fatty acids, such as oleic acid, 513 
confer a higher solubilization capacity to mixed micelles, since despite that the lipid 514 
digestion in terms of FFA release of the HPO-containing SLNs was much lower than 515 
MCT LLNs and GS-containing SLNs, they presented a higher β-carotene 516 
bioaccessibility (Figure 5B). In fact, oleic acid concentration in the micelle fraction 517 
increased with increasing the HPO concentration in the lipid blend, which was the only 518 
23 
 
lipid species positively correlated with the β-carotene bioaccessibility (data not shown). 519 
In agreement to this, other authors have reported that the fatty acid saturation degree 520 
might determine the micellarization capacity of mixed micelles, since monounsaturated 521 
FFA were related to a higher carotenoid bioaccessibility in comparison with 522 
polyunsaturated FFA (Verkempinck, Salvia-Trujillo, Moens, Carrillo, et al., 2018). 523 
Moreover, differences have been reported in the lipid digestion preference of intestinal 524 
lipases, being digested first the unsaturated fatty acids followed by monounsaturated 525 
and finally polyunsaturated fatty acids (Pascoviche, Goldstein, Fishman, & Lesmes, 526 
2019). In this context, our results evidence that monounsaturated long chain FFA, such 527 
as oleic acid, might contribute in a higher extent compared to saturated long chain FFA 528 
such as palmitic acid, to the micellarization of β-carotene. 529 
 530 
4 Conclusions 531 
Results of the present research contribute to understanding the role of the lipid type and 532 
state on the colloidal stability and lipid digestion kinetics of solid lipid nanoparticles 533 
(SLNs) as carriers of lipophilic bioactive ingredients and the relationship between the 534 
micelle fraction composition and their bioaccessibility. In this regard, the lipid 535 
hydrolysis might be determined not only by the crystallization state of the lipid used for 536 
the formulation of SLNs but also by the chain length of the lipid type. The solidification 537 
of lipid phase consisting on a medium chain triglyceride oil (MCT) with a 538 
monoglyceride molecule such as glyceryl stearate (GS) does not affect the lipolysis 539 
reaction of SLNs during small intestine conditions whereas hydrogenated palm oil 540 
(HPO), which is mainly composed of long chain fatty acids, significantly slows down 541 
the lipid hydrolysis kinetics and diminishes its extent, which may be attributed to the 542 
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type of fat crystals formed with HPO-containing SLNs, hindering the adsorption of 543 
intestinal lipases at the oil-water interface. Additionally, it was evidenced that the β-544 
carotene bioaccessibility and therefore the solubilization capacity of mixed micelles is 545 
not determined by the concentration of lipid digestion products in the micelle fraction 546 
but by the type of lipid species. Namely, the presence of monounsaturated long chain 547 
fatty acids, such as oleic acid, and long chain monoacylglycerols in the micelle fraction 548 
contribute in enhancing the β-carotene bioaccessibility. Hence, this work provides novel 549 
insights on the behavior of SLNs under digestion conditions and the possibility to 550 
modulate the formulation the solid lipid phase for a targeted lipid digestibility with 551 
optimal bioaccessibility of encapsulated lipophilic bioactive compounds. 552 
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Figure 1. Average particle diameter (µm) of nanoemulsions and solid lipid nanoparticles formulated 667 
with different lipid phases consisting on a medium chain tryglyceride (MCT) and glyceryl stearate 668 
(GS) at different concentrations (A) or hydrogenated palm oil (HPO) at different ratios (B) initially 669 
and after being submitted to simulated gastric and small intestinal conditions.  670 
Different lower case letters indicate significant differences between different GIT phases for the same type of 671 
lipid phase. Different upper case letters indicate significant differences between samples for the same GIT phase 672 












































































Figure 2. Particle size distribution in intensity (%) of nanoemulsions and solid lipid nanoparticles formulated with different lipid phases 676 
consisting on a medium chain tryglyceride (MCT) mixed with glyceryl stearate (GS) at different concentrations (A, B, and C) or with 677 
hydrogenated palm oil (HPO) (D, E, F) initially (A, D) and after being submitted to simulated gastric (B, E) and small intestinal conditions (C, 678 
F).  679 
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Figure 3. ζ-potential (mV) of nanoemulsions and solid lipid nanoparticles formulated with different lipid 681 
phases consisting on a medium chain tryglyceride (MCT) and glyceryl stearate (GS) at different 682 
concentrations (A) or hydrogenated palm oil (HPO) at different ratios (B) initially and after being 683 
submitted to simulated gastric and small intestinal conditions.  684 
Different lower case letters indicate significant differences between different GIT phases for the same type of 685 
lipid phase. Different upper case letters indicate significant differences between samples for the same GIT phase 686 
and different lipid phase. 687 
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Figure 4. Lipid digestion kinetics expressed as free fatty acid release (%) during small intestinal time 691 
(min) of nanoemulsions and solid lipid nanoparticles formulated with different lipid phases consisting 692 
on a medium chain tryglyceride (MCT) and glyceryl stearate (GS) at different concentrations (A, C) or 693 
hydrogenated palm oil (HPO) at different ratios (B, D). Lipid digestion kinetics up to 35 min of 694 
intestinal phase was modelled using a sigmoidal equation and full symbols represent experimental data 695 
points and lines are predicted values. Full, dotted, dashed and dotted-dashed lines correspond to MCT, 696 
MCT-0.5% GS, MCT-1% GS and MCT-5% GS or MCT:HPO 100:0, 50:50, 25:75 and 0:100. 697 
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Figure 5. β-carotene bioaccessibility (%) (lines) in relation of the lipid digestibility in terms of free fatty 700 
acid release (%) (bars) at the end of the in vitro small intestinal phase (120 min) of nanoemulsions and 701 
solid lipid nanoparticles formulated with different lipid phases consisting on a medium chain 702 
tryglyceride (MCT) and glyceryl stearate (GS) at different concentrations (A) or hydrogenated palm oil 703 
(HPO) at different ratios (B). 704 
Lower case letters indicate significant differences between the β-carotene bioaccessibility values while 705 
different upper case letters indicate significant differences between the free fatty acid release. 706 



































































































Figure 6. Micelle fraction composition in terms of free fatty acids (A,C) and monoacylglycerides (B, D) 710 
of nanoemulsions and solid lipid nanoparticles formulated with different lipid phases consisting on a 711 
medium chain tryglyceride (MCT) and glyceryl stearate (GS) at different concentrations (A, B) or 712 
hydrogenated palm oil (HPO) at different ratios (C, D). 713 




Figure A. Differential scanning calorimetry profiles of the lipid phases used for the formulation of 716 
liquid lipid nanoparticles with MCT (A) or solid lipid nanoparticles with MCT blended with 717 
glyceryl stearate (GS) at a concentration of 0.5, 1 and 5 % (w/w) (B, C and D, respectively). 718 
Upper lines are the cooling cicles and lower lines are the heating cycles. The crystallization (Tc) 719 
and melting (Tm) temperatures are provided for each peak and its respective difference of enthalpy 720 
(ΔHf).    721 
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Figure B. Differential scanning calorimetry profiles of the lipid phases used for the formulation of 724 
liquid lipid nanoparticles with MCT (A) or solid lipid nanoparticles with MCT blended with 725 
hydrogenated palm oil (HPO) at a ratio of 50:50, 25:75 and 0:100 of MCT:HPO (B, C and D, 726 
respectively). Upper lines are the cooling cicles and lower lines are the heating cycles. The 727 
crystallization (Tc) and melting (Tm) temperatures are provided for each peak and its respective 728 
difference of enthalpy (ΔHf).    729 
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Figure C. Microscopy images of liquid lipid nanoparticles and solid lipid nanoparticles 733 
formulated with different lipid phases consisting on a medium chain tryglyceride (MCT) and 734 
glyceryl stearate (GS) at different concentrations initially and after being submitted to simulated 735 
gastric and small intestinal conditions. 736 
 737 
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Figure D. Microscopy images of liquid lipid nanoparticles and solid lipid nanoparticles 739 
formulated with different lipid phases consisting on a medium chain tryglyceride (MCT) and 740 
hydrogenated palm oil (HPO) at different concentrations initially and after being submitted to 741 
simulated gastric and small intestinal conditions. 742 
 743 
 744 
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Table A. Estimated kinetic parameters of the logistic model fitted to experimental data of free 746 
fatty acid release of liquid or solid lipid nanoparticles formulated with medium chain triglyceride 747 
oil (MCT) or MCT containing different concentrations of glyceryl stearate (GS) during the first 35 748 
min of in vitro small intestinal phase. 749 
Sample k a b R2 
MCT 0.351 ± 0.013 a 8.515 ± 0.129 a 86.34 ± 0.96 a 0.997 
MCT+GS 0.5 % 0.348 ± 0.013 a 8.585 ± 0.136 a 89.12 ±1.04 a 0.997 
MCT+GS 1 % 0.328 ± 0.011 a 9.344 ± 0.130 b 94.13 ± 1.03 b 0.997 
MCT+GS 5 % 0.346 ± 0.012 a 8.955 ± 0.129 ab 98.37 ± 1.09 c 0.997 
k is the kinetic rate constant, a is the inflexion point of the curve and b is the asymptotic parameter. Different lower case levels 750 




Table B. Estimated kinetic parameters of the logistic model fitted to experimental data of free 755 
fatty acid release of liquid or solid lipid nanoparticles formulated with medium chain triglyceride 756 
oil (MCT) or hydrogenated palm oil (HPO) and their blends at different ratios during the first 35 757 
min of in vitro small intestinal phase. 758 
Sample k a b R2 
MCT: HPO (100:0) 0.351 ± 0.013 b 8.515 ± 0.129 b 86.34 ± 0.96 d 0.997 
MCT:HPO (50:50) 0.476 ± 0.015 cc 6.625 ± 0.079 a 75.56 ± 0.55 c 0.998 
MCT:HPO (25:75) 0.460 ± 0.130 cc 8.460 ± 0.130 b 67.75 ± 0.83 b 0.996 
MCT:HPO (0:100) 0.209 ± 0.022 a 16.328 ± 0.796 c 56.92 ± 2.55 a 0.997 
k is the kinetic rate constant, a is the inflexion point of the curve and b is the asymptotic parameter. Different lower case levels 759 
indicate statistically significant differences in the same estimated kinetic parameter between the different lipid phases of the lipid 760 
nanoparticles. 761 
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